The Innovative Medicines Initiative (IMI) is a European initiative to improve the competitive situation of the European Union in the field of pharmaceutical research. The IMI is a joint initiative (public-private partnership) of the DG Research of the European Commission, representing the European Communities, and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI is laid out as a Joint Technology Initiative within the Seventh Framework Programme. Michel Goldman was the first executive director, from September 2009 until December 2014.
| Attributes | Values |
|---|
| rdf:type
| |
| rdfs:label
| - Innovative Medicines Initiative (de)
- Innovative Medicines Initiative (en)
- Innovative Medicines Initiative (nl)
|
| rdfs:comment
| - Innovative Medicines Initiative (IMI) ist eine Initiative zur Steigerung der Wettbewerbsfähigkeit der pharmazeutischen Forschungseinrichtungen in der Europäischen Union. Die IMI ist ein Public-Private-Partnership der Europäischen Kommission und der EFPIA, der European Federation of Pharmaceutical Industries and Associations (deutsch: Europäische Vereinigung von pharmazeutischen Industrien und Verbänden). IMI ist Teil der 7. Forschungsrahmenprogramms. Aktuell geförderte Projekte sind unter anderem: (de)
- The Innovative Medicines Initiative (IMI) is a European initiative to improve the competitive situation of the European Union in the field of pharmaceutical research. The IMI is a joint initiative (public-private partnership) of the DG Research of the European Commission, representing the European Communities, and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI is laid out as a Joint Technology Initiative within the Seventh Framework Programme. Michel Goldman was the first executive director, from September 2009 until December 2014. (en)
- Het Innovative Medicines Initiative (IMI) is een Europees initiatief om de concurrentiepositie van de Europese Unie te verbeteren op het gebied van onderzoek in de farmacotherapie. Het IMI is een gezamenlijk initiatief (publiek-private samenwerking) van het van de Europese Commissie (EC), met vertegenwoordiging van de Europese gemeenschap en de Europese federatie van farmaceutische industrie en verenigingen (EFPIA). IMI is opgezet als een binnen het zevende . (nl)
|
| foaf:name
| - Innovative Medicines Initiative (en)
|
| foaf:homepage
| |
| name
| - Innovative Medicines Initiative (en)
|
| foaf:depiction
| |
| dcterms:subject
| |
| Wikipage page ID
| |
| Wikipage revision ID
| |
| Link from a Wikipage to another Wikipage
| |
| Link from a Wikipage to an external page
| |
| sameAs
| |
| dbp:wikiPageUsesTemplate
| |
| thumbnail
| |
| budget
| |
| end
| |
| funding
| |
| funding agency
| |
| keywords
| |
| project type
| |
| start
| |
| title
| - Joint Technology Initiative on Innovative Medicines (en)
|
| website
| |
| has abstract
| - Innovative Medicines Initiative (IMI) ist eine Initiative zur Steigerung der Wettbewerbsfähigkeit der pharmazeutischen Forschungseinrichtungen in der Europäischen Union. Die IMI ist ein Public-Private-Partnership der Europäischen Kommission und der EFPIA, der European Federation of Pharmaceutical Industries and Associations (deutsch: Europäische Vereinigung von pharmazeutischen Industrien und Verbänden). IMI ist Teil der 7. Forschungsrahmenprogramms. Aktuell geförderte Projekte sind unter anderem: - EMTRAIN: European Medicines Research Training Network, deutsch: Europäisches Medizin-Forschungs-Ausbildungs-Netzwerk - Eu2P: European programme in Pharmacovigilance and Pharmacoepidemiology, deutsch: Europäisches Programm zu Nebenwirkungen (Pharmakovigilanz) und Wirkungen von Arzneimitteln in der Bevölkerung (Pharmakoepidemiologie) - Pharmatrain: Pharmaceutical Medicine Training Programme, deutsch: Pharmazeutisches Medizin-Ausbildungs-Programm - SafeSciMET: European Modular Education and Training Programme in Safety Sciences for Medicines, deutsch: Europäisches modulares Erziehungs- und Ausbildungs-Programm in Sicherheitswissenschaften für die Medizin (de)
- The Innovative Medicines Initiative (IMI) is a European initiative to improve the competitive situation of the European Union in the field of pharmaceutical research. The IMI is a joint initiative (public-private partnership) of the DG Research of the European Commission, representing the European Communities, and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI is laid out as a Joint Technology Initiative within the Seventh Framework Programme. Michel Goldman was the first executive director, from September 2009 until December 2014. The Innovative Medicines Initiative is aimed towards removing research bottlenecks in the current drug development process. The IMI Joint Technology Initiative (IMI JTI), to be implemented by the IMI Joint Undertaking is meant to address these research bottlenecks. Its €2bn budget makes it the largest biomedical public-private partnership in the world. The funding scheme has been criticised, requiring universities to invest more money than with EU FP7 programs. Besides the non-competitive financial aspects of participation in IMI projects for academia, this criticism also discusses that intellectual property is freely flowing to industry. The Sixth Framework Programme's research projects InnoMed AddNeuroMed and InnoMed PredTox acted as pilot projects establishing the feasibility of this particular public-private partnership. Since then, the IMI has had four funding rounds: the first call had the topic Safety, while the second call was about Efficacy. Projects for these two calls are ongoing. The IMI 2 started in 2014 and will run until 2024, while the IMI 1 is still running. Overall budget is €3.276 billion, taken for half from the European Horizon 2020 program. Goals of that second calls are to improve clinical trials success rate, deliver clinical proof of concept, biomarkers and new medicines. (en)
- Het Innovative Medicines Initiative (IMI) is een Europees initiatief om de concurrentiepositie van de Europese Unie te verbeteren op het gebied van onderzoek in de farmacotherapie. Het IMI is een gezamenlijk initiatief (publiek-private samenwerking) van het van de Europese Commissie (EC), met vertegenwoordiging van de Europese gemeenschap en de Europese federatie van farmaceutische industrie en verenigingen (EFPIA). IMI is opgezet als een binnen het zevende . Het Innovatieve Medicijnen Initiatief is gericht op het overkomen van de knelpunten binnen de huidige ontwikkeling van geneesmiddelen. Het IMI wordt gefinancierd door de EC en de EFPIA in Brussel en heeft een budget van € 2 miljard, waarmee het de grootste biomedische publiek-private samenwerking ter wereld is. Er is eerder kritiek geweest op de manier van financiering, waarbij universiteiten een groter deel zouden moeten investeren dan bij EU-financieringsprogramma's. Naast de non-competitieve financiële kanten van de samenwerking in IMI-projecten voor universiteiten belicht dit commentaar ook het punt van toegang tot intellectueel eigendom. Als pilootprojecten werden in het voorgaande zesde raamwerkprogramma de onderzoeksprojecten InnoMed AddNeuroMed en InnoMed PredTox opgezet, om het samenwerkingsverband uit te proberen. Het IMI heeft al meerdere funding rounds gedaan: de eerste oproep had het onderwerp veiligheid, de tweede oproep ging over effectiviteit. (nl)
|
| framework programme
| |
| research objective
| - Re-invigorate the European bio-pharmaceutical sector and to make Europe more attractive for private research and development investment in this sector (en)
|
| gold:hypernym
| |
| skos:closeMatch
| |
| project budget total ($)
| |
| prov:wasDerivedFrom
| |
| page length (characters) of wiki page
| |
| title
| - Joint Technology Initiative on Innovative Medicines (en)
|
| project budget funding ($)
| |
| project keyword
| - Drug discovery,Drug development
|
| foaf:isPrimaryTopicOf
| |
| is Link from a Wikipage to another Wikipage
of | |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)
